AbbVie: FDA OKs QULIPTA® (atogepant) for Adults With Chronic Migraine

 

• QULIPTA^® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic
• Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activities
• Approval based on a clinical trial that demonstrated statistically significant reduction from baseline in mean monthly migraine days and improvements in function and reduction in activity impairment
• AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine

https://www.biospace.com/article/releases/u-s-fda-approves-qulipta-atogepant-for-adults-with-chronic-migraine/